Bora Pharmaceuticals to Purchase Emergent’s Sterile Manufacturing Facility


The acquisition of the 87,000 square-foot Camden, MD plant provides the CDMO with the ability to offer clinical and commercial non-viral aseptic fill-finish services on four fill lines.

Image Credit: Adobe Stock Images/

Image Credit: Adobe Stock Images/

As part of the company’s commercial plan, Bora Pharmaceuticals Co., Ltd., a contract development and manufacturing organization (CDMO), will be acquiring Emergent BioSolutions’ 87,000 square-foot sterile manufacturing facility in Baltimore-Camden, MD.1 The current site’s staff will also have the option to join the Bora team if they elect to do so.

The plant offers drug product manufacturing services for sterile injectables, while also featuring clinical and commercial non-viral aseptic fill-finish services on four fill lines, including pre-filled syringe filling, vials filling, and lyophilization.

This deal offers several benefits to Bora. For one, the CDMO can now provide drug substance and drug product services. It also conveniently balances the company’s development and manufacturing offering for biologics developers, Bora Biologics.

“This transaction not only demonstrates our commitment to our growth strategy and plans for expansion in North America, but also enables us to expand our offering for our biologics customers,” noted Bobby Sheng, Bora Group’s chairman and CEO. “We look forward to working with the hugely talented team at the facility and supporting new and existing customers as we grow and develop the facility.”

The future of the sterile injectable market seems bright—trends are indicating growth, while a Research and Markets report2 predicts that market size will surpass $1 trillion by 2030 at a six-year compound annual growth rate of 10.17%. The report also addresses questions surrounding which products, segments, applications, and areas in the sector one should consider investing in over the forecast period, along with regulatory frameworks and technology trends in the market. Also in the works for Bora are ideas to further develop the aforementioned facility.

When it comes to the theme of US-based acquisitions, the CDMO capitalized off the momentum from its purchase of Upsher-Smith Laboratories, a generics manufacturer based in Minnesota, earlier this year.3

“This is a significant milestone for Bora Group, marking the most critical expansion of Bora’s presence in the US market and significantly enhancing Bora’s position as a global competitor with regard to its CDMO business and commercial Rx business,” added Sheng at the time of the acquisition. “Upsher-Smith’s competitiveness is a perfect match to Bora’s long-term growth—its newly-expanded, USFDA-approved manufacturing facilities, with a total capacity of 3.5 billion doses, will be Bora’s first local facility in the US, establishing a crucial stronghold for our global CDMO business. Upsher-Smith’s platform for specialty generics will strengthen TWi’s advantage in the US commercial sale business with a complementary portfolio and differentiated distribution channels.”

This latest deal seemed like the next logical step in the company’s growth strategy, which features plans to not only continue growing its sterile drug product manufacturing know-how, but to do so on North American soil.


1. Bora Pharmaceuticals Expands North American Footprint with Agreement to Acquire First Sterile Manufacturing Facility. Bora Pharmaceuticals. June 20, 2024. Accessed June 20, 2024.

2. Global Sterile Injectable Drugs Market by Molecule Type (Large Molecule, Small Molecule), Drug (Blood Factors, Cytokines, Immunoglobulins), Indication, Distribution - Forecast 2024-2030. Research and Markets. March 2024. Accessed June 20, 2024.

3. Bora Pharmaceuticals Expands North American Footprint with Agreement to Acquire First Sterile Manufacturing Facility. Pharmaceutical Commerce. January 23, 2024. Accessed June 20, 2024.

Recent Videos
© 2024 MJH Life Sciences

All rights reserved.